Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 3/20 | 0.33 |
| ▸ | RORA | P35398 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17365774 | 0.94 | ALOX5AP (0.36) | RORCAPPCTSLCTSSCTSK | |
| SCHEMBL17368008 | 0.93 | APP (0.34) | RORCAPPCTSLCTSSCTSK | |
| SCHEMBL17367992 | 0.91 | CTSL (0.34) | RORCAPPCTSLCTSSCTSK | |
| SCHEMBL17368019 | 0.90 | CTSK (0.36) | RORCAPPCTSLCTSSCTSK | |
| SCHEMBL17368010 | 0.90 | APP (0.34) | RORCAPPCTSLCTSSCTSK | |
| SCHEMBL17365836 | 0.89 | CTSL (0.35) | CTSLCTSSCTSKGRM2 | |
| SCHEMBL17365975 | 0.87 | CTSL (0.34) | RORCAPPCTSLCTSSCTSK | |
| SCHEMBL17368028 | 0.87 | CTSL (0.36) | RORCCTSLCTSSCTSK | |
| SCHEMBL17365835 | 0.86 | ALOX5AP (0.34) | RORCAPPCTSLCTSSCTSK | |
| SCHEMBL17368018 | 0.86 | CTSL (0.34) | CTSLCTSSCTSKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20150376504-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | PIEZO1, ROCK1, RCC1 | RORC 1705/4885APP 1099/4885CTSL 2885/4885 |
| US-20150376504-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, ROCK1, RCC1 | RORC 1705/4885APP 1099/4885CTSL 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.